Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.38 |
| ▸ | HTR2C | P28335 | 9/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255348 | 1.00 | HTR2A (0.38) | HTR2AHTR2CMCHR1SLC6A2L3MBTL1 | |
| SCHEMBL18959352 | 1.00 | HTR2A (0.38) | HTR2AHTR2CMCHR1SLC6A2L3MBTL1 | |
| SCHEMBL13860754 | 0.88 | SIGMAR1 (0.38) | HTR2AHTR2CL3MBTL1 | |
| SCHEMBL10104203 | 0.86 | HTR2A (0.44) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL25917213 | 0.83 | MCHR1 (0.35) | HTR2AHTR2CMCHR1SLC6A2NCF1 | |
| SCHEMBL18898059 | 0.83 | MCHR1 (0.35) | HTR2AHTR2CMCHR1SLC6A2NCF1 | |
| SCHEMBL19114994 | 0.83 | HTR2A (0.33) | HTR2AHTR2CMCHR1NCF1 | |
| SCHEMBL19226483 | 0.83 | HTR2A (0.33) | HTR2AHTR2CMCHR1NCF1 | |
| SCHEMBL14883743 | 0.81 | — | — | |
| SCHEMBL24477230 | 0.80 | ALDH1A1 (0.39) | HTR2AHTR2CMCHR1SLC6A2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022262784-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2022-12-22 | — | — | WO | disclosed |
| WO-2022001916-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2022-01-06 | — | — | WO | disclosed |
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | HTR2A 1220/4885HTR2C 735/4885MCHR1 4209/4885 |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | HTR2A 1220/4885HTR2C 735/4885MCHR1 4209/4885 |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | MCHR1, MCHR2, MC1R | HTR2A 76/4885HTR2C 106/4885MCHR1 1/4885 |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | HTR2A 1220/4885HTR2C 735/4885MCHR1 4209/4885 |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | HTR2A 1220/4885HTR2C 735/4885MCHR1 4209/4885 |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | HTR2A 1220/4885HTR2C 735/4885MCHR1 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.